Status:
UNKNOWN
Prevalence and Pathological Features of C3 Dominant Glomerulonephritis Among Egyptian Population
Lead Sponsor:
Sohag University
Conditions:
C3 Nephropathy
Eligibility:
All Genders
Brief Summary
A classification has introduced C3 glomerulopathy (C3 glomerulopathy consensus report) that should be used to designate a disease process due to abnormal control of complement activation, deposition, ...
Eligibility Criteria
Inclusion
- Adequate sample with at least 10 glomeruli
- Enough residual tissues in the paraffin blocks
- Available clinical data
Exclusion
- Other glomerular diseases such as lupus nephritis, IgA nephropathy, membranous glomerulonephritis and immune complex-mediated membranoproliferative GN. Cases of minimal change were also excluded.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06126471
Start Date
November 1 2023
End Date
December 1 2024
Last Update
November 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag university , faculty of medicine
Sohag, Egypt